



Joy brings us together

KIRIN R&D DAY 2020


Opening Remarks

October 6, 2020


Yoshinori Isozaki
President & CEO
Kirin Holdings Company, Limited

KV2027


Long-Term Management Vision “Kirin Group Vision 2027”



Create new value through solving the social issues
Creating Shared Value



Organizational capabilities for innovation



Evolution of our business model — History (1)



The Kirin Group has achieved growth by leveraging its core technologies to address unmet needs



1885
Japan Brewery is established
 Producing authentic German-style beer to meet the needs of foreign residents in Japan

1907
Kirin Brewery Company is established

1928
Enters the soft drink business with the launch of Kirin Lemon
 Kirin Lemon, which contained no artificial colors or sweeteners, later satisfied a growing public awareness of the quality and safety of food and beverages

1982
R&D Department is established
 Gene design and fermentation technologies combined to enter the pharmaceutical business

1990
ESPO® launched
 First drug addressing unmet needs, including renal anemia, launched in partnership with U.S.-based Amgen




Japan Brewery Plant

Manufacturing technology (incl. packaging technology) Engineering technology



The soft drink production line at the Yokohama Plant

Fermentation and biotechnology



Research report recommending entry into the pharmaceutical business (1981)



Erythropoietin production (roller bottle) system developed by Kirin




ESPO® when it was first released


Evolution of our business model — History (2)



Embracing a research-driven spirit founded upon fermentation and biotechnology, we have enhanced our research and development capabilities to search for microorganisms and create cell culture-based production technologies



Kirin Group's core competencies and value creation



Value Creation

Core competencies
Foundations for driving innovations

Consumer centric marketing expertise

ICT accelerating value creation


Diversity and inclusion, culture for innovation

Kirin fermentation and biotechnology R&D drawn from 100+ years of experience




Kirin's robust fermentation and biotechnology R&D is world-leading

FERMENTATION & BIOTECHNOLOGY



Kirin Group's Business Domains



Part 1

Opening remarks

09:05 – 09:15

Kirin Holdings Company, Limited

Yoshinori Isozaki, President & CEO

Session 1 R&D at the Kirin Group

- Expanding the Kirin Group's technological capabilities and business domains
- Technical capabilities to solve social issues

09:15 – 10:05

Kirin Holdings Company, Limited

Noriaki Kobayashi, Director of the Board &
Senior Executive Officer (presenter/Q&A)

Break (10 minutes)

Session 2 Discovery and Promise of *Lactococcus lactis* strain Plasma, Conversation with Guests

10:15 – 11:00

- Joint Research and Results of Research on *Lactococcus lactis* strain Plasma
- Potential of *Lactococcus lactis* strain Plasma

Yasuhiro Nishizaki, Senior Executive Director, Tokai University Tokyo Hospital

Daisuke Fujiwara, Deputy General Manager, Health Science Department, Kirin Holdings Company, Limited

Part 2

Poster Presentations by the Researchers

11:00 – 12:00

Products Registered as “Foods with Function Claims”

Joy brings us together



For the first time ever, an Immune System Support Food was registered with Japan’s Consumer Affairs Agency (CAA)

The CAA has publicly released a notification of *Foods with Function Claims* With Kirin’s 5 of core *L. lactis* strain *Plasma** Products

**Lactococcus lactis* strain Plasma

First time an immune system-related product has been registered in Japan



It is now possible to label these products with “Supports maintenance of the immune system in healthy individuals”

**A vital step towards becoming a global leader in CSV
Contributing to maintaining health of the global community**

Part 1

Opening remarks

09:05 – 09:15

Kirin Holdings Company, Limited

Yoshinori Isozaki, President & CEO

Session 1 R&D at the Kirin Group

- Expanding the Kirin Group's technological capabilities and business domains
- Technical capabilities to solve social issues

09:15 – 10:05

Kirin Holdings Company, Limited

Noriaki Kobayashi, Director of the Board &
Senior Executive Officer (presenter/Q&A)

Break (10 minutes)

Session 2 Discovery and Promise of *Lactococcus lactis* strain Plasma, Conversation with Guests

10:15 – 11:00

- Joint Research and Results of Research on *Lactococcus lactis* strain Plasma
- Potential of *Lactococcus lactis* strain Plasma

Yasuhiro Nishizaki, Senior Executive Director, Tokai University Tokyo Hospital

Daisuke Fujiwara, Deputy General Manager, Health Science Department, Kirin Holdings Company, Limited

Part 2

Poster Presentations by the Researchers

11:00 – 12:00

The purpose of a company lies
in the solution of social issues.

Societies need companies that can continue to
contribute to solving problems,
even in the midst of environmental changes that
no one could have predicted.

The Kirin Group is committed to CSV management
while pursuing sustainable growth,
even in the midst of uncertainty and unpredictability

Aim to be a global leader in CSV by solving the issues
of the global community
while turning the solutions into opportunities for growth

This material is intended for informational purposes only and is not a solicitation or offer to buy or sell securities or related financial instruments.



よろこびがつなぐ世界へ Joy brings us together